Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis

L Manzoli; Me Flacco; Stefania Boccia; E D’Andrea; N Panic; C Marzuillo; R Siliquini; Walter Ricciardi; P Villari; Jp Ioannidis

Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis

L Manzoli, Me Flacco, Stefania Boccia, E D’Andrea, N Panic, C Marzuillo, R Siliquini, Walter Ricciardi, P Villari, Jp Ioannidis

Risultato della ricerca: Contributo in rivista › Contributo a convegno

Abstract

Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.

Lingua originale	English
pagine (da-a)	74-74
Numero di pagine	1
Rivista	European Journal of Public Health
Volume	25
Stato di pubblicazione	Pubblicato - 2015
Evento	8th European Public Health Conference - Milano Durata: 14 ott 2015 → 17 ott 2015

Keywords

cardiovascular diseases
meta-analysis

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Altri file e collegamenti

Link a IRIS PubliCatt

Cita questo

@article{c410902128cf4c9b950c4528e822114b,

title = "Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis",

abstract = "Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.",

keywords = "cardiovascular diseases, meta-analysis, cardiovascular diseases, meta-analysis",

author = "L Manzoli and Me Flacco and Stefania Boccia and E D{\textquoteright}Andrea and N Panic and C Marzuillo and R Siliquini and Walter Ricciardi and P Villari and Jp Ioannidis",

year = "2015",

language = "English",

volume = "25",

pages = "74--74",

journal = "European Journal of Public Health",

issn = "1101-1262",

publisher = "Oxford University Press",

note = "8th European Public Health Conference ; Conference date: 14-10-2015 Through 17-10-2015",

}

TY - JOUR

T1 - Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis

AU - Manzoli, L

AU - Flacco, Me

AU - Boccia, Stefania

AU - D’Andrea, E

AU - Panic, N

AU - Marzuillo, C

AU - Siliquini, R

AU - Ricciardi, Walter

AU - Villari, P

AU - Ioannidis, Jp

PY - 2015

Y1 - 2015

N2 - Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.

AB - Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.

KW - cardiovascular diseases

KW - meta-analysis

KW - cardiovascular diseases

KW - meta-analysis

UR - http://hdl.handle.net/10807/70743

M3 - Conference article

SN - 1101-1262

VL - 25

SP - 74

EP - 74

JO - European Journal of Public Health

JF - European Journal of Public Health

T2 - 8th European Public Health Conference

Y2 - 14 October 2015 through 17 October 2015

ER -

Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis

Abstract

Keywords

OSS delle Nazioni Unite

Altri file e collegamenti

Fingerprint

Cita questo